EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Biomarkers in Alzheimer's disease clinical trials: 2025

Amanda M Leisgang Osse iD, Yadi Zhou, Jefferson W Kinney, Andrew Hooyman, Ayan Sengupta, Jorge Fonseca, Aaron H Burstein, Meriel Owen, Laura Nisenbaum, Howard M Fillit, Feixiong Cheng, Jeffrey L Cummings

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2026-01 · 12 (1)

DOI: 10.1002/trc2.70217 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 17.02.2026. Verfasst von Amanda M Leisgang Osse und 11 weiteren Autor:innen. Beteiligte Einrichtung: Chambers-Grundy Center for Transformative Neuroscience Department of Brain Health Kirk Kerkorian School of Medicine University of Nevada Las Vegas (U…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarkers play an important role in Alzheimer's disease (AD) clinical trials in several contexts of use, including defining trial eligibility and serving as outcome measures. Utilizing clinicaltrials.gov, a registry of clinical trials, we assessed biomarker usage across all active AD disease‐targeted therapeutic (DTT) trials. Biomarkers are widely used in AD DTT trials, with 84% including a fluid, imaging, and/or digital biomarker, either as an inclusion criterion or as an outcome measure. In DTT trials, biomarkers were included in 83% of Phase 3 trials, 91% of Phase 2 trials, and 72% of Phase 1 trials. Biomarkers were used for trial inclusion in 58% of DTT trials and as a primary outcome measure in 36%. Characterization of biomarker usage in AD clinical trials offer valuable insights across the drug development spectrum, with the goal of increasing trial efficiency and interpretation, while reducing time for new therapies to become available.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkersclinical trialcommon Alzheimer's disease research ontologydrug development

Autor:innen und Institutionen

  • Chambers-Grundy Center for Transformative Neuroscience Department of Brain Health Kirk Kerkorian School of Medicine University of Nevada Las Vegas (UNLV) Las Vegas Nevada USA.
  • Department of Brain Health Kirk Kerkorian School of Medicine University of Nevada Las Vegas (UNLV) Las Vegas Nevada USA.
  • Genomic Medicine Institute Cleveland Clinic Research Cleveland Clinic Cleveland Ohio USA.
  • Department of Physical Therapy Chapman University Irvine California USA.
  • Department of Health Physics and Diagnostic Sciences School of Integrated Health Sciences University of Nevada Las Vegas (UNLV) Las Vegas Nevada USA.
  • Howard R Hughes College of Engineering Department of Computer Science University of Nevada Las Vegas (UNLV) Las Vegas Nevada USA.

ORCID-Profile: Amanda M Leisgang Osse

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • NIGMS NIH HHS
  • Alzheimer's Drug Discovery Foundation

Zitieren

APA

Osse, A. M. L., Zhou, Y., Kinney, J. W., Hooyman, A., Sengupta, A., Fonseca, J., Burstein, A. H., Owen, M., Nisenbaum, L., Fillit, H. M., Cheng, F., & Cummings, J. L. (2026). Biomarkers in Alzheimer's disease clinical trials: 2025. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 12(1). https://doi.org/10.1002/trc2.70217

Vancouver

Osse AML, Zhou Y, Kinney JW, Hooyman A, Sengupta A, Fonseca J, et al. Biomarkers in Alzheimer's disease clinical trials: 2025. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2026;12(1). doi:10.1002/trc2.70217

BibTeX
@article{Osse2026,
  author = {Osse, Amanda M Leisgang and Zhou, Yadi and Kinney, Jefferson W and Hooyman, Andrew and Sengupta, Ayan and Fonseca, Jorge and Burstein, Aaron H and Owen, Meriel and Nisenbaum, Laura and Fillit, Howard M and Cheng, Feixiong and Cummings, Jeffrey L},
  title = {Biomarkers in Alzheimer's disease clinical trials: 2025},
  journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
  year = {2026},
  volume = {12},
  number = {1},
  doi = {10.1002/trc2.70217}
}
Kostenlos starten →